Cells · 2022 · 24 citations · 30 references
MedicineOncologyUrologyMolecular OncologyNeoplasiaTumor ProgressionAngiogenesisAngiogenesis In CancerCancer Cell SignalingCancer ProgressionMalignant NeoplasmsUrothelial CarcinomaAngiogenic BiomarkersClinical Outcome MeasurementEndothelial Tube FormationMicrovascular DensityTumor Angiogenesis SignalingTumor Growth DynamicsVascular Endothelial Growth Factor InhibitionVegf Pathway Inhibition
BACKGROUND AND PURPOSE: This research aimed to excavate the alternative mechanism of CEBPD on tumor growth and explore the biological significance of the CEBPD/hsa-miR-429/VEGFA axis on angiogenesis in urothelial carcinoma (UC). METHODS: Quantitative RT-PCR, immunoblotting assay and tube formation examined the effect of hsa-miR-429 mimic or/and inhibitor on VEGFA expression and angiogenesis in CEBPD-overexpressing UC-derived cells. The association between CEBPD, hsa-miR-429, VEGFA and microvascular density (MVD) and clinical outcome were evaluated in 296 patients with UBUC and 340 patients with UTUC, respectively. RESULTS: The increase in the transcript and protein of VEGFA as well as HUVECs tube formation was diminished upon the treatment of hsa-miR-429 mimic in CEBPD-overexpressing BFTC909 and TCCSUP. Nevertheless, the inhibited regulation of hsa-miR-429 mimic on the expression of VEGFA and ability of HUVECs tube formation was rescued by the combined incubation with hsa-miR-429 inhibitor in these two UC-derived cell lines. Furthermore, the clinical correlations showed that the higher level of VEGFA or MVD has a positive correlation with the expression of CEBPD and a negative relation to hsa-miR-429 and leads to tumor aggressiveness with worse disease-specific, metastasis-free survival in UBUC and UTUC cohorts. CONCLUSIONS: We decipher the oncogenic mechanism of CEBPD on angiogenesis through the hsa-miR-429 inhibition to stabilize the expression of VEGFA in UC. The novel research unveiled the modulation of the CEBPD/hsa-miR-429/VEGFA axis on the progression of UC and could be accessible to theranostic biomarkers.
30
Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 679 citations · Full text
Medicine, Gynecology, Oncology +6
Kaladhar B. Reddy · Cancer Cell International · 2015 · 612 citations · Full text
Aristolochic acid-associated urothelial cancer in Taiwan
Chung‐Hsin Chen, Kathleen G. Dickman, Masaaki Moriya et al. · Proceedings of the National Academy of Sciences · 2012 · 414 citations · Full text